Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from August 14, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 12, 2025 — +11.6% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$78.56 – $80.01Entry zone — fair-value band

$81.24Published — price the day we called it

$88.53Target — the price the thesis aimed for

$92.12Peak — highest point inside the window, not a realized return

$90.68Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 49 days.

At window close

+11.6%

realized, from the publication price to the last close inside the window

Peak gain

+13.4%

peak, from the publication price — not a realized return

S&P 500, same window

+6.3%

SPY over the identical days, dividend-adjusted

Window close

$90.68

last close inside the window, ended November 12, 2025

Peak price

$92.12

peak on November 12, 2025 — not a realized return

Days to target

The thesis — published August 14, 2025

Predicted growth

+11%

over the measurement window

Target price

$88.53

the price the thesis aimed for

Entry zone

$78.56 – $80.01

the fair-value band we waited for

Price at publication

$81.24

published August 14, 2025

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck looks like a steady, lower-drama choice, with trading action improving and strong interest from large investors. A well-known checklist (Peter Lynch style) rated it 93%. Recent results were muddied by one-time costs, so upcoming comparisons should look cleaner. With the recent average price trend getting healthier, buying small amounts on dips makes sense, aiming for about 11% upside while watching drug news and policy changes.

Primary drivers

Stable drug maker that can hold up in rough markets; big investors like it.
Scored 93% on a respected stock-picking checklist many investors follow.
One-time costs made recent results look messy; future reports should look cleaner.
Recent average price trend improving, making step-by-step buys reasonable.

How it played out

MRK: target reached in 49 days

Lyra published MRK at $81.24 on 2025-08-14 with an 11% expected gain and an $88.53 target. The thesis pointed to a stable drug maker, interest from large investors, a 93% checklist score, messy recent results tied to one-time costs, and an improving recent average price trend.

Inside the window, MRK reached the target in 49 days. It peaked at $92.12 on 2025-11-12, a 13.4% gain, and ended at $90.68. The published thesis played out on price. The stock reached the target and stayed above it at the end.

What happened during the window

On 2025-09-19, the FDA approved pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection. On 2025-10-30, Merck reported third-quarter sales of $17.28 billion and adjusted earnings per share of $2.58, according to Investor's Business Daily.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals